Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2026-02-20 00:00:00 ET · period of report 2026-02-19 · accession 0001933414-26-000045 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-20 | 2026-02-19 | MLYS | Congleton Jon | CEO, Dir | A - Grant | $0.00 | +140.9K | 780.1K | +22% | $0 |
| D | 2026-02-20 | 2026-02-19 | MLYS | Congleton Jon | CEO, Dir | A - Grant | $0.00 | +187.9K | 187.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-19 | A | A | 140,900 | $0.00 | 780,051 | D | — | — | (F1) Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant. |
| 2 | Derivative | Stock Option | 2026-02-19 | A | A | 187,900 | $0.00 | 187,900 | D | $28.06 · — to 2036-02-19 | 187,900 Common Stock | (F2) The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant |